Horizon shells out $510M for access to gout med Kyrstexxa

Carly Helfand Horizon may have quit on its hostile pursuit of California's Depomed, but that doesn't mean it's quit on dealmaking altogether. On the contrary, on Friday ...

With Roche in the rear view mirror, Constellation Pharma grabs $55M round

John Carroll FierceBiotech News

The most popular FierceBiotech stories of 2015

Alok Saboo FierceBiotech News

Stepped-up Nucynta sales push starts paying off for Depomed

Tracy Staton Depomed's relaunch of the Nucynta franchise–purchased earlier this year from Johnson & Johnson–is off to a running start, the company said last week ...

Boehringer Ingelheim picks family member to lead it through tough times

Eric Palmer Boehringer Ingelheim has picked a member of the founding family as CEO for the first time in a quarter of a century to help it through its lean times. The drugmaker announced ...

GenSight scuttles its planned $65M IPO

Damian Garde GenSight Biologics has postponed its plans to go public after repeatedly downsizing its ambition, marking the latest setback for Wall Street-bound biotechs dealing with ...

AstraZeneca walks back some of its immuno-oncology ambition

Damian Garde AstraZeneca, working to catch up with Merck and Bristol-Myers Squibb in the growing field of immuno-oncology, said its treatment is unlikely to win speedy approval in lung ...

Witty insists GSK’s safe approach, backed by innovative pipeline, is the way to success

Eric Palmer GlaxoSmithKline CEO Andrew Witty continues to take heat for moving the U.K. drugmaker heavier into low-margin areas like consumer health and vaccines. But he continues ...

GOP’s Rubio joins the pharma-bashing trend, slamming ‘profiteering’ on price hikes

Tracy Staton The drug-pricing debate has moved to the Republican side of the aisle. GOP candidate Sen. Marco Rubio joined the fray in New Hampshire over the weekend, by slamming "pure ...

The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews

Damian Garde Big Pharma has been willing to pay hundreds of millions of dollars for a shortcut to FDA approval, buying up priority review vouchers created to incentivize new drugs for ...

Sources: Sanofi’s Brandicourt looks at spinoff of animal health, selling supplement biz

Eric Palmer New Sanofi CEO Olivier Brandicourt has promised to unveil his 5-year strategic plan for the French drugmaker and he appears to be homing in on what to keep and ...

Intas CEO expects to break into U.S. biosimilar market yet this year

Eric Palmer The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's Neulasta, a drug it developed with Canada's Apotex. FiercePharma ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS